157068-00-3

Usage

Uses

Used in Pharmaceutical Synthesis:
Ethanone, 2-bromo-1-(4-chloro-2-hydroxyphenyl)is used as an intermediate in the synthesis of pharmaceuticals for its unique structural properties. Its presence in the molecular structure can contribute to the development of new drugs with potential therapeutic applications.
Used in Organic Compounds Synthesis:
Ethanone, 2-bromo-1-(4-chloro-2-hydroxyphenyl)is also used as a building block in the synthesis of various organic compounds, where its specific functional groups can be utilized to create a wide range of chemical products with different properties and uses.
Used in Medical Research:
Ethanone, 2-bromo-1-(4-chloro-2-hydroxyphenyl)is used in medical research as a potential candidate for the development of new therapeutic agents. Its chemical structure may offer insights into the design of novel drugs with improved efficacy and reduced side effects.
Used in Biochemical Studies:
In the field of biochemistry, Ethanone, 2-bromo-1-(4-chloro-2-hydroxyphenyl)- may be employed in studies aimed at understanding the interactions between molecules and biological systems. Its unique structure could provide valuable information on molecular recognition and binding processes, which are crucial for the development of new bioactive molecules.

Upstream product

• 6921-66-0 4-chloro-2-hydroxy acetophenone 

Downstream Products

• 402929-55-9 1-(4-chloro-2-hydroxyphenyl)-2-(1H-1,2,4-triazol-1-yl)ethanone 
• 402929-57-1 1-(4-chloro-2-hydroxyphenyl)-2-(4H-1,2,4-triazol-4-yl)ethanone 
• 80930-53-6 1-(4-chloro-2-hydroxy-phenyl)-2-imidazol-1-yl-ethanone 
• 1315362-39-0 2-azido-1-(4-chloro-2-hydroxyphenyl)ethanone 
• 3260-78-4 6-chlorobenzofuran-3(2H)-one 

Relevant academic research and scientific papers

3-Hydroxychromone structure-based Raf kinase inhibitor, and preparation method and use thereof

The invention relates to the field of pharmaceutical chemistry, and concretely relates to 3-hydroxychromone compounds (A). R1-R9, X1 and X2 in the compounds (A) are as defined in the description. The invention also discloses preparation methods of the compounds represented by general formula (A), a medicinal composition containing the compounds, and a medicinal use of the compounds, especially a use of the compounds as a Raf kinase inhibitor and a tumor inhibitor.

INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

Compounds of formula (I): wherein R4, R6 and R7 are defined herein, are useful as inhibitors of HIV replication.

INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

Compounds of formula (I): wherein c, X, Y, R2, R4 and R5 are defined herein, are useful as inhibitors of HIV replication.

INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

The present invention relates to compounds of formula (I) wherein c, X, Y, R2, R3, R4 and R6 are as defined herein, compositions and uses thereof for treating human immunodeficiency virus (HIV) infection. In particular, the present invention provides novel inhibitors of HIV integrase, pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HIV infection

INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

Compounds of formula I : wherein c, R2, R3, R4, R5, R6, R7 and R8 are defined herein, are useful as inhibitors of HIV replication.

2-Hydroxyphenacyl azoles and related azolium derivatives as antifungal agents

2-Hydroxyphenacyl azole and 2-hydroxyphenacyl azolium compounds have been described as a new class of azole antifungals. Most target compounds showed significant in vitro antifungal activities against tested fungi (Candida albicans, Saccharomyces cerevisiae, Aspergillus niger, and Microsporum gypseum) with low MICs values included in the range of 0.25-32 μg/mL comparable to reference drug fluconazole. The most active compounds were also assessed for their cytotoxicity using MTT colorimetric assay on normal mouse fibroblast (NIH/3T3) cells. The results of antifungal activity and toxicity tests indicated that these compounds display antifungal activity at non-cytotoxic concentrations.